We’ve recently updated our valuation analysis.

Xenon Pharmaceuticals Valuation

Is XENE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 4/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XENE?

Other financial metrics that can be useful for relative valuation.

XENE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue67.7x
Enterprise Value/EBITDA-16.5x
PEG Ration/a

Price to Book Ratio vs Peers

How does XENE's PB Ratio compare to its peers?

XENE PB Ratio vs Peers
The above table shows the PB ratio for XENE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average16.1x
SAGE Sage Therapeutics
XNCR Xencor
TWST Twist Bioscience
INSM Insmed
XENE Xenon Pharmaceuticals

Price-To-Book vs Peers: XENE is good value based on its Price-To-Book Ratio (2.8x) compared to the peer average (16.1x).

Price to Earnings Ratio vs Industry

How does XENE's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: XENE is expensive based on its Price-To-Book Ratio (2.8x) compared to the US Biotechs industry average (1.6x)

Price to Book Ratio vs Fair Ratio

What is XENE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XENE PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate XENE's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of XENE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: XENE ($35.53) is trading below our estimate of fair value ($54.88)

Significantly Below Fair Value: XENE is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies